Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy

Several histone deacetylase inhibitors including Vorinostat have received FDA approval for the treatment of haematological malignancies. However, data from these trials indicate that Vorinostat has limited efficacy as a monotherapy, prompting the need for rational design of combination therapies. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Hay, Jodie F., Lappin, Katrina, Liberante, Fabio, Kettyle, Laura M., Matchett, Kyle B., Thompson, Alexander, Mills, Ken I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620222/
https://www.ncbi.nlm.nih.gov/pubmed/28978082
http://dx.doi.org/10.18632/oncotarget.18910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620222/
https://www.ncbi.nlm.nih.gov/pubmed/28978082
http://dx.doi.org/10.18632/oncotarget.18910

Ejemplares similares